ERYtech Pharma Announces Enrollment Of First Patient In Phase II Study Of ERY-ASP In Pancreatic Cancer
7/28/2014 10:30:46 AM
LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by